AI pharmaceuticals on the wind mouth of drug companies layout enthusiastic

Novo Nordisk has stated that the company has entered into a collaboration agreement with US-based technology company Valo Health seeking to develop new therapies for cardiometabolic diseases (CMDs) using human data and artificial intelligence technology. Utilizing AI technology can shorten the development cycle of new drugs and save costs.